摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

十九烷-1-硫醇 | 53193-23-0

中文名称
十九烷-1-硫醇
中文别名
——
英文名称
1-nonadecanethiol
英文别名
nonadecane-1-thiol;Nonadecylmercaptan;Nonadecan-1-thiol
十九烷-1-硫醇化学式
CAS
53193-23-0
化学式
C19H40S
mdl
——
分子量
300.593
InChiKey
YNESSCJHABBEIO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    9.9
  • 重原子数:
    20
  • 可旋转键数:
    17
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    1
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    十九烷-1-硫醇sodium hydroxide 、 cobalt phthalocyaninetetrasulphonamide 、 氧气 作用下, 以 为溶剂, 20.0 ℃ 、101.32 kPa 条件下, 反应 2.0h, 以98%的产率得到dinonadecyl disulfide
    参考文献:
    名称:
    COBALT PHTHALOCYANINE MEDIATED AEROBIC OXIDATION OF THIOLS: A SIMPLE AND CONVENIENT PREPARATION OF DISULPHIDES
    摘要:
    Cobalt phthalocyaninetetrasulphonamide/tetrasodium salt of cobalt tetrasulphophthalocyanine catalyzed oxidation with molecular oxygen form a simple, efficient and environmentally acceptable synthetic tool for the oxidation of thiols to disulphides in excellent yields, under mild conditions and without any side reactions.
    DOI:
    10.1081/scc-120003604
  • 作为产物:
    描述:
    1-溴十九烷 、 sodium hydroxide 作用下, 以 乙醇 为溶剂, 生成 十九烷-1-硫醇
    参考文献:
    名称:
    自组装单层电荷传输的奇偶效应
    摘要:
    本文比较了包含奇数和偶数亚甲基的正链烷硫醇自组装单层 (SAM) 的电荷传输。超平坦模板剥离的银 (Ag(TS)) 表面支撑 SAM,而共晶镓铟 (EGaIn) 的顶部电极与 SAM 接触以形成金属/SAM//氧化物/EGaIn 结。EGaIn 自发地与环境氧反应形成薄 (~1 nm) 氧化物层。该氧化层使 EGaIn 能够保持稳定的圆锥形状(便于形成与 SAM 的微接触),同时保持接触硬表面时变形和流动的能力。EGaIn 的锥形电极(至少部分地)符合 SAM 并产生高产量的工作结。Ga(2)O(3)/EGaIn 顶部电极能够在方便的时间段内收集具有统计意义的数据。在具有奇数和偶数亚甲基的正链烷硫醇之间观察到的电荷传输差异 - “奇偶效应” - 使用这些连接在统计上是可辨别的,并表明该技术对结构和性质的微小差异敏感SAM。具有偶数个亚甲基的烷硫醇表现出预期的电流密度 J 指数下降,随着链长
    DOI:
    10.1021/ja1090436
点击查看最新优质反应信息

文献信息

  • CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF
    申请人:Fujifilm Corporation
    公开号:US20210155644A1
    公开(公告)日:2021-05-27
    An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides an anti-adenoviral agent including a compound represented by General Formula [1] (in the formula, R 1 represents a hydrogen atom, a halogen atom, an amino group which may be substituted, a monocyclic nitrogen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a monocyclic nitrogen- and oxygen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; and X represents an oxygen atom or a sulfur atom) or a salt thereof.
    本发明的一个目的是提供一种作为抗腺病毒药剂具有优异药效的化合物,以及一种抗腺病毒药剂。本发明提供了一种包括由通式[1]表示的化合物的抗腺病毒药剂 (在公式中,R 1 表示氢原子、卤素原子、可能被取代的基、可能被取代的单环氮含杂环基团(前提是形成环的氮原子与R 1 结合的碳原子相结合)、可能被取代的单环氮和氧含杂环基团(前提是形成环的氮原子与R 1 结合的碳原子相结合)、可能被取代的C 1-6 烷氧基、可能被保护的羟基等;R 2 表示氢原子或基保护基团;R 3 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的基等;R 4 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的基等;X表示氧原子或原子)或其盐。
  • QUENCHER
    申请人:Wako Pure Chemical Industries, Ltd.
    公开号:US20170342031A1
    公开(公告)日:2017-11-30
    A quencher is disclosed having a compound represented by the following general formula (1): wherein R 5 each independently represent a halogen atom, an alkyl group, an alkoxy group, an alkylthio group, an amino group having a substituent or not having a substituent, a hydroxy group, an aryl group, an aryloxy group, or an arylalkyl group; R 6 represents a group having a polymerizable unsaturated group, a hydroxy group, or the like; Y 1 represents an oxygen atom, or the like; An − represents an anion; Ar 1 represents a specific ring structure; * and ** represent binding positions; Ar 2 represents a benzene ring, a naphthalene ring, or an anthracene ring; n 1 represents a specific integer; and the following structure (1-10) in the general formula (1) is an asymmetric structure; (wherein R 5 , Y 1 , Ar 1 , Ar 2 , n 1 , * and ** are the same as described above.).
    一种淬灭剂被公开,该淬灭剂具有以下一般公式(1)表示的化合物: 其中R5各自独立代表一个卤素原子、一个烷基团、一个烷氧基团、一个烷基团、一个带有或不带有取代基的基团、一个羟基、一个芳基团、一个芳氧基团或一个芳烷基团;R6代表一个具有可聚合不饱和基团、一个羟基或类似基团的集团;Y1代表一个氧原子或类似;An代表一个阴离子;Ar1代表一个特定的环结构;*和**代表结合位置;Ar2代表一个苯环、一个环或一个环;n1代表一个特定的整数; 并且一般公式(1)中的以下结构(1-10)是一个不对称结构; (其中R5、Y1、Ar1、Ar2、n1、*和**与上述描述相同)。
  • CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF
    申请人:FUJIFILM Corporation
    公开号:US20210147456A1
    公开(公告)日:2021-05-20
    An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides a compound represented by General Formula [1] (in the formula, R 1 represents a halogen atom, an amino group which may be substituted, a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like); or a salt thereof.
    本发明的一个目的是提供一种作为抗腺病毒药剂的化合物,以及一种抗腺病毒药剂。本发明提供一种由通式[1]表示的化合物 (在该式中,R 1 代表卤原子,可能被取代的基,可能被取代的C 1-6 烷氧基,可能被保护的羟基等;R 2 代表氢原子或基保护基;R 3 代表可能被取代的C 1-20 烷氧基,可能被取代的芳氧基,可能被取代的基等;R 4 代表可能被取代的C 1-20 烷氧基,可能被取代的芳氧基,可能被取代的基等);或其盐。
  • Organic Semiconductor Material
    申请人:Miyata Yasuo
    公开号:US20110087034A1
    公开(公告)日:2011-04-14
    A dihydroindacene compound represented by the following formula (1): wherein R 1 is identical or different from each other, and each denotes a hydrogen atom, alkyl which may be substituted, alkenyl which may be substituted, alkynyl which may be substituted, alkoxy which may be substituted, alkylthio which may be substituted, aryl which may be substituted, aryloxy which may be substituted, or the like; R 2 to R 5 are identical or different from each other, and each denote a hydrogen atom, alkyl which may be substituted, alkenyl which may be substituted, or the like; p is 0, 1, or 2; and ring structures A and B are identical or different from each other, and each denote a benzene ring which may be substituted, a thiophene ring which may be substituted, or the like.
    一种二氢吲哚嗪化合物,其由以下式(1)表示:其中R1彼此相同或不同,各自表示氢原子、可被取代的烷基、可被取代的烯基、可被取代的炔基、可被取代的烷氧基、可被取代的烷基、可被取代的芳基、可被取代的芳氧基等;R2至R5彼此相同或不同,各自表示氢原子、可被取代的烷基、可被取代的烯基等;p为0、1或2;环结构A和B彼此相同或不同,各自表示可被取代的苯环、可被取代的噻吩环等。
  • Molecular Origin of the Odd–Even Effect of Macroscopic Properties of <i>n</i>-Alkanethiolate Self-Assembled Monolayers: Bulk or Interface?
    作者:Fadwa Ben Amara、Eric R. Dionne、Sahar Kassir、Christian Pellerin、Antonella Badia
    DOI:10.1021/jacs.0c04288
    日期:2020.7.29
    of the dielectric constant and surface hydrophobicity originate from changes in the polymethylene chain conformation (bulk), while the odd-even variation arises primarily from a difference in the chemical com-position of the interface related to the terminal group orientation. These findings provide new physical insights into the structure-property relation of SAMs for the design of ultrathin film dielectrics
    阐明单层界面与体积对化学锚定到属表面的有机自组装单层 (SAM) 的宏观特性(例如,表面疏性、电荷传输和电子转移)的影响是一个挑战。本文报道了通过电化学阻抗谱和接触角测角法在宏观尺度上和通过红外反射吸收在分子平上表征 (CH3(CH2)nSAu,n = 6-19) 上的正链烷醇的原型 SAM光谱学。SAM 电容、介电常数和表面疏性取决于聚亚甲基链的长度 (n) 和奇偶校验(nodd 或 neven)。 拉伸模式的峰值位置表明随着 n = 6 和 16 之间的 n 增加,链构象顺序逐渐增加。 nodd 的 SAM 比 neven 的 SAM 具有更大程度的结构 gauche 缺陷。 拉伸模式的峰值强度和位置与链长无关,但显示出 末端空间取向的奇偶交替。不同数据趋势之间的相关性表明,介电常数和表面疏性的链长依赖性源于聚亚甲基链构象(本体)的变化,而奇偶变化主要
查看更多